Combined targeting of synthetic lethal partners in RB1-deficient cells
Description: Project narrative RB1 is a tumor suppressor gene that is frequently mutated in various tumors, including retinoblastomas, small cell lung cancers, triple-negative breast cancers, prostate cancers, and osteosarcomas. Despite extensive studies of pRb family proteins, a therapeutic approach that specifically targets defects in this tumor suppressor is currently not available, underscoring the need for alternative strategies that can identify new targets for cancers with inactivated RB1. We propose to identify a pair of FDA-approved drugs targeting synthetic lethal partners of RB1 to develop a novel personalized therapy for RB1-mutated tumors.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R03
Start date: 2024-01-01
End date: 2025-12-31
Investigator: ANDREY A PARKHITKO
Institution: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
Funded outputs count: 7
Funder award ID: R03CA286521
OpenAlex ID: G9000876692